ClinicalTrials.gg
CompletedNCT01088529Updated May 15, 2014Results posted

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

A Phase 2 interventional study of Abiraterone Acetate and Prednisone in Prostate Cancer, sponsored by Cougar Biotechnology, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-15.

Sponsored by Cougar Biotechnology, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
41st of 69
66 · median 77
Started
2009
with 4 others
Phase 2
23 of 70
4 open now
Registered
25th of 70
by date

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 41st largest by enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2009, is one of 23 in phase 2, and was the 25th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical research study is to find out how treatment with abiraterone acetate in combination with prednisone and a Luteinizing Hormone-Releasing Hormone (LHRH) analogue changes the tumor in comparison to treatment with an LHRH analogue alone.

Objectives:

Primary Objective:

To assess the difference in pathologic stage \< pT2 between Group A and Group B.

Secondary Objective:

  • To assess and compare the changes in levels of androgens (pre, during, and post treatment) in the serum, primary tumor microenvironment and bone marrow between Group A and Group B.
  • To assess changes in biomarkers related to androgen signaling and other cancer-related pathways between Group A and Group B.
  • To assess the difference in rate of positive surgical margins between Group A and Group B.
  • To assess the safety profile of abiraterone acetate and low dose prednisone in a preoperative setting.
Read the detailed description

Study Groups:

Participants who are eligible to take part in this study will be randomly assigned (as in the flip of a coin) to 1 of 2 groups:

  • Those who are in Group A will take abiraterone acetate, a LHRH analogue, and prednisone.
  • Those who are in Group B will receive a LHRH analogue alone. Participants will have 2 out of 3 chances of being placed in Group A or 1 out of 3 chances of being placed in Group B.

Participants in both groups will receive the study drug(s) for about 3 months followed by a prostatectomy (prostate surgery) between 2 and 4 weeks after they stop taking the study drug(s).

Length of Study:

Participants will receive study drugs on this study for about 3 months before having surgery to remove their prostate about 2-4 weeks later. Participants will be removed from this study if the disease gets worse, if they experience intolerable side effects, or their study doctors feel that it is in their best interest to stop the study.

Long-Term Follow-Up:

Participants will return to the clinic 1 month, 3 months, 6 months, and then every 6 months (for up to 8 years) after your surgery for follow-up visits. Up to 66 patients will be take part in this study. All will be enrolled at M. D. Anderson after their surgery.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Neoadjuvant Prostate Cancer
  • Abiraterone Acetate
  • LHRHa
  • high risk prostate cancer
  • Radical prostatectomy
  • Prednisone
  • Luteinizing Hormone-Releasing Hormone
  • LHRH analogue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological proof of prostatic adenocarcinoma via a minimum of 6 core samples
  2. Clinical stage T1c or T2 with high-grade disease (Gleason's 8-10) on initial biopsy, or clinical stage T2b-T2c with Gleason's grade >/= 7 and PSA > 10ng/ml.
  3. No evidence of disease as determined by CT scans and bone scans.
  4. (ECOG) Performance Status of \</= 1
  5. Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (ANC) > 1,500 and count of > 100,000.
  6. Normal pituitary and adrenal function
  7. Patients should be deemed to be candidates for radical prostatectomy.

Exclusion criteria

Exclusion Criteria:

  1. Histological variants in the primary tumor (histological variants other than adenocarcinoma); neuroendocrine tumor
  2. Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
  3. Uncontrolled hypertension
  4. Abnormal Liver function
  5. Active or symptomatic viral hepatitis or chronic liver disease
  6. heart disease
  7. Other active
  8. History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
  9. Previous treatment with abiraterone acetate
  10. Patients who are not appropriate surgical candidates for radical prostatectomy
  11. Prior chemotherapy or radiation therapy for prostate cancer.
  12. Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study

Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    AA+LHRHa

    Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) and 1,000 mg abiraterone acetate (AA) plus 5 mg of prednisone daily for 3 months prior to radical prostatectomy.

    Drug: Abiraterone Acetate · Drug: Prednisone · Drug: LHRHa

  • Experimental
    LHRHa

    Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) prior to radical prostatectomy.

    Drug: LHRHa

Interventions

  • 1000 mg oral daily for 3 months followed by a prostatectomy.

    Also known as: CB7630

  • 5 mg orally daily.

  • DrugLHRHa

    LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.

    Also known as: Lupron®, leuprolide, Zoladex®, goserelin

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2)

    The table below shows number of participants in each treatment group with a pathology tumor stage less than or equal to pT2.

    Time frame: At the end of Cycle 3 (at radical prostatectomy)

Secondary outcomes

  1. Number of Participants With a Positive Surgical Margin at Radical Prostatectomy

    The table below shows number of participants in each treatment group who had positive surgical margins. A positive surgical margin is defined as tumor extending to the inked-surface or margin of the prostate.

    Time frame: At the end of Cycle 3 (at radical prostatectomy)

  2. Number of Participants With Prostate-Specific Antigen Response

    The table below shows number of participants in each treatment group who achieved a prostate-specific antigen (PSA) response defined as a drop in PSA value to less than or equal to 0.2 ng/mL.

    Time frame: Cycle 3 Day 1

07

Results

Posted Apr 9, 2014

Participant flow

The study was conducted from 20 November 2009 to 14 March 2013. Participants were recruited at 1 study center in the United States.

Participant flow — Overall Study
MilestoneAA+LHRHaLHRHa
Started4422
Received treatment4421
Completed4421
Not completed01
Withdrew: Did not receive study treatment01

Outcome measures

PrimaryNumber of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2)

The table below shows number of participants in each treatment group with a pathology tumor stage less than or equal to pT2.

Time frame:
At the end of Cycle 3 (at radical prostatectomy)
Reported as:
Number · participants
Number of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2)
participantsAA+LHRHaLHRHa
Number of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2)248
Statistical analysis
  • AA+LHRHa vs LHRHa · Chi-squared · p = 0.2148 · Relative risk: 1.432 · 90% CI 0.859 to 2.386
SecondaryNumber of Participants With a Positive Surgical Margin at Radical Prostatectomy

The table below shows number of participants in each treatment group who had positive surgical margins. A positive surgical margin is defined as tumor extending to the inked-surface or margin of the prostate.

Time frame:
At the end of Cycle 3 (at radical prostatectomy)
Reported as:
Number · participants
Number of Participants With a Positive Surgical Margin at Radical Prostatectomy
participantsAA+LHRHaLHRHa
Number of Participants With a Positive Surgical Margin at Radical Prostatectomy66
Statistical analysis
  • AA+LHRHa vs LHRHa · Fisher Exact · p = 0.1796 · Relative risk: 0.477 · 90% CI 0.205 to 1.109
SecondaryNumber of Participants With Prostate-Specific Antigen Response

The table below shows number of participants in each treatment group who achieved a prostate-specific antigen (PSA) response defined as a drop in PSA value to less than or equal to 0.2 ng/mL.

Time frame:
Cycle 3 Day 1
Reported as:
Number · participants
Number of Participants With Prostate-Specific Antigen Response
participantsAA+LHRHaLHRHa
Number of Participants With Prostate-Specific Antigen Response320
Statistical analysis
  • AA+LHRHa vs LHRHa · Chi-squared · p = <0.0001 · Relative risk: 6.523 · 90% CI 2.701 to 15.753

Adverse events

Collected over 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA+LHRHa—2/44 (4.5%)43/44 (97.7%)
LHRHa—2/21 (9.5%)21/21 (100%)
Most frequent serious events
Most frequent serious events
EventAA+LHRHaLHRHa
Gastric IleusGastrointestinal disorders0/441/21
Pelvic AbscessInfections and infestations0/441/21
Infected LymphoceleInfections and infestations1/440/21
Rib FractureInjury, poisoning and procedural complications1/440/21
Bone PainMusculoskeletal and connective tissue disorders1/440/21
Most frequent other events
Showing 10 of 29
Most frequent other events
EventAA+LHRHaLHRHa
Hot FlushVascular disorders37/4418/21
AnaemiaBlood and lymphatic system disorders23/448/21
Alanine Aminotransferase IncreasedInvestigations22/447/21
FatigueGeneral disorders19/4410/21
Aspartate Aminotransferase IncreasedInvestigations17/447/21
InsomniaPsychiatric disorders3/446/21
HypercholesterolaemiaMetabolism and nutrition disorders9/445/21
HypertensionVascular disorders10/443/21
HyperglycaemiaMetabolism and nutrition disorders9/443/21
HyperbilirubinaemiaHepatobiliary disorders8/441/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)AA+LHRHaLHRHaTotal
Mean61.6 ± 7.1459.9 ± 7.661 ± 7.29
Sex: Female, Male
Sex: Female, Male(Participants)AA+LHRHaLHRHaTotal
Female000
Male442266
08

Study locations

1 site
  • Houston, Texas, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2010
First posted
Mar 17, 2010
Start
Dec 2009
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Apr 9, 2014
Last update
May 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01088529
Responsible party
Sponsor
First posted
Mar 17, 2010
Start date
Dec 2009
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Apr 9, 2014
Last update
May 15, 2014

Study contacts

Cougar Biotechnology, Inc. Clinical Trial
study director · Cougar Biotechnology, Inc.
Christopher Logothetis, MD
principal investigator · UT MD Anderson Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion